Pre-cardioversion Anticoagulation Duration — EECC MCQ

Correct answer: C — If AF duration is >24 hours or unknown, the 2024 ESC AF Guidelines require ≥3 weeks of therapeutic anticoagulation before cardioversion (or TOE to exclude LA thrombus); 5 weeks exceeds this minimum and cardioversion can proceed if adherence to apixaban is confirmed — post-cardioversion OAC for ≥4 weeks is mandatory

Pre-cardioversion anticoagulation per 2024 ESC AF Guidelines: (1) AF ≤24 hours: cardioversion can proceed without prior OAC or TOE (reduced from 48h in 2020 guidelines); (2) AF >24 hours or unknown duration: EITHER ≥3 weeks therapeutic OAC (with confirmed adherence) OR TOE to exclude LA/LAA thrombus before cardioversion; (3) Post-cardioversion: ≥4 weeks OAC regardless of CHA₂DS₂-VA (to cover the 'stunning' period — LA mechanical function recovers over weeks, during which thrombus risk persists); (4) Long-term OAC decision based on CHA₂DS₂-VA score (≥2 = lifelong OAC; 1 = consider). This patient: 5 weeks of apixaban exceeds the 3-week minimum. KEY: adherence must be confirmed (missed DOAC doses during the 3-week window increase thrombus risk — unlike warfarin, DOACs have no confirmatory monitoring like INR). If adherence is uncertain, TOE should be performed.

Reference: ESC (2024): AF Guidelines